Status:
COMPLETED
Venous to Arterial Carbon Dioxide Difference (P₍ᵥ-ₐ₎CO₂): Predictor of Septic Patient Prognosis Depending on the ScvO₂
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Septic Shock
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
the investigators will include 120 patients with a diagnosis of septic shock in accordance with the definition given by the 2001 expert consensus. Two groups of patients are likely to participate in t...
Eligibility Criteria
Inclusion
- Patient with a diagnosis of septic shock
- Initial lactate in patients should be≥ 2 mmol / L.
- The presence of circulatory insufficiency defined by a systolic blood pressure ≤ 90 mmHg (or a drop in blood pressure≥ 50 mmHg in hypertensive patients)
- One or more of the following: oliguria defined as diuresis≤ 0,5 mL/ kg / h for at least two hours; the presence of signs of cerebral hypoperfusion; the highlighting of mottling
- The presence of a femoral arterial catheter and a central venous line in the superior vena cava position
- Hemodynamic monitoring with semi-invasive monitoring of cardiac output with thermodilution
Exclusion
- Patient no longer in the initial phase of septic shock
- Absence of semi-invasive cardiac monitoring with thermodilution
- Vulnerable people
- Absence of informed consent
Key Trial Info
Start Date :
June 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2019
Estimated Enrollment :
124 Patients enrolled
Trial Details
Trial ID
NCT03292120
Start Date
June 1 2016
End Date
May 1 2019
Last Update
May 8 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assisitance Publique Hopitaux de Marseille
Marseille, France, 13354